Unilife Corporation announced that the FDA has granted market clearance for its Unitract 1mL insulin syringes assembled at its Lewisberry, PA facility. Unitract 1mL insulin syringes assembled at Unilife’s Shanghai, China facilities first received FDA clearance in August 2008.
The Unitract 1mL insulin syringe allows control of the speed of passive (automatic) needle retraction directly from the patient’s body into the barrel of the syringe where it is locked in place. Unitract 1mL insulin syringes may help prevent the transmission of blood-borne diseases (eg, HIV and hepatitis C) via needlestick injuries, aerosol dispersal, and syringe reuse.
For more information call (800) 324-7674 or visit www.unilife.com.